Philip R. Tracy
Directeur/Membre du Conseil chez Viamet Pharmaceuticals Corp.
Profil
Mr. Phil R.
Tracy is a Principal at Intersouth Partners.
He joined Intersouth Partners in 1997.
He was previously employed as President & Chief Executive Officer by Burroughs Wellcome from 1974 to 1995.
Earlier, most of his career was spent at Burroughs Wellcome Co., a major research-based pharmaceutical company.
At Burroughs Wellcome, he served as President and CEO from 1989 until the company's merger with Glaxo in 1995.
Mr. Tracy is Chairman at Alimera Sciences, Inc. since 2004, and Counsel at Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan LLP.
He is on the Board of Directors at Argos Therapeutics, Inc. since 2004.
Mr. Tracy received a B.A.
from the University of Nebraska and a J.D.
and L.L.B.
from George Washington University.
Postes actifs de Philip R. Tracy
| Sociétés | Poste | Début |
|---|---|---|
Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan LLP
 Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan LLP Miscellaneous Commercial ServicesCommercial Services Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan LLP provides legal services. The private company is based in Raleigh, NC. | Conseiller Juridique Général | 06/01/2014 |
| Intersouth Associates V LLC | Directeur/Membre du Conseil | - |
| Intersouth Associates IV LLC | Directeur/Membre du Conseil | - |
Viamet Pharmaceuticals Corp.
 Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | Directeur/Membre du Conseil | 01/01/2015 |
Anciens postes connus de Philip R. Tracy
| Sociétés | Poste | Fin |
|---|---|---|
| ALIMERA SCIENCES, INC. | Président | 06/05/2015 |
| Burroughs Wellcome | Directeur Général | 01/01/1995 |
Viamet Pharmaceuticals, Inc.
 Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | Directeur/Membre du Conseil | - |
The Burroughs Wellcome Fund
 The Burroughs Wellcome Fund Investment Trusts/Mutual FundsMiscellaneous The Burroughs Wellcome Fund is a private foundation located in Research Triangle Park, NC. The private company's mission is to serve and strengthen society by nurturing a diverse group of leaders in biomedical sciences to improve human health through education and powering discovery in frontiers of greatest need. The CEO of the company is Louis J. Muglia. | Directeur/Membre du Conseil | - |
Intersouth Partners
 Intersouth Partners Investment ManagersFinance Intersouth Partners (Intersouth Partners) is a venture capital firm founded in 1985 by Dennis Dougherty and Roy Rodwell. The firm is headquartered in Durham, North Carolina. | Private Equity Investor | - |
Formation de Philip R. Tracy
| University of Nebraska | Undergraduate Degree |
| George Washington University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ALIMERA SCIENCES, INC. | Health Technology |
| Entreprise privées | 9 |
|---|---|
Argos Therapeutics, Inc.
 Argos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Argos Therapeutics, Inc. was a biopharmaceutical company. It engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. The firm's product include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Bruce A. Sullenger, Eli Gilboa, John A. Irick and Ralph M. Steinman on May 8, 1997 and was headquartered in Durham, NC. | Health Technology |
Intersouth Partners
Intersouth Partners Investment ManagersFinance Intersouth Partners (Intersouth Partners) is a venture capital firm founded in 1985 by Dennis Dougherty and Roy Rodwell. The firm is headquartered in Durham, North Carolina. | Finance |
Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan LLP
Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan LLP Miscellaneous Commercial ServicesCommercial Services Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan LLP provides legal services. The private company is based in Raleigh, NC. | Commercial Services |
| Burroughs Wellcome | |
The Burroughs Wellcome Fund
The Burroughs Wellcome Fund Investment Trusts/Mutual FundsMiscellaneous The Burroughs Wellcome Fund is a private foundation located in Research Triangle Park, NC. The private company's mission is to serve and strengthen society by nurturing a diverse group of leaders in biomedical sciences to improve human health through education and powering discovery in frontiers of greatest need. The CEO of the company is Louis J. Muglia. | Miscellaneous |
| Intersouth Associates V LLC | |
| Intersouth Associates IV LLC | |
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | Health Technology |
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | Health Technology |